FierceBiotech 2025-12-08 Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets
FierceBiotech 2025-12-08 AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE
FierceBiotech 2025-12-07 ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch
FierceBiotech 2025-12-07 ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success
FierceBiotech 2025-12-06 ‘Market’s thinking is backwards’: FDA’s 1-trial approval plan would boost R&D spend, Jefferies says
FierceBiotech 2025-12-05 Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data
FierceBiotech 2025-12-05 'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out
FierceBiotech 2025-12-05 How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle
FierceBiotech 2025-12-05 Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA
FierceBiotech 2025-12-05 Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability
FierceBiotech 2025-12-04 GE HealthCare, Mayo Clinic launch digital twin project for personalizing radiation cancer therapy
FierceBiotech 2025-12-04 Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche’s Flatiron
FierceBiotech 2025-12-04 After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg
FierceBiotech 2025-12-04 Crescent waxes pipeline with $80M Kelun deal, bagging ADC to pair with PD-1xVEGF bispecific